[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Conditions](https://durgical.com/en/conditions/) › Connective tissue disease–associated interstitial lung disease

# Connective tissue disease–associated interstitial lung disease

Lung scarring or inflammation caused by autoimmune diseases such as [scleroderma](https://durgical.com/en/conditions/systemic-sclerosis/), [rheumatoid arthritis](https://durgical.com/en/conditions/rheumatoid-arthritis/) or myositis. Early screening and treatment help.

Updated Nov 15, 2026

On this page

- The basics What it is
- How to think about it
- Who gets it
- Causes
- Risk factors
- Pathophysiology
- Classification
- Common traps
- Why it happens

- Clinical Symptoms and signs
- Red flags
- Diagnosis
- Differential diagnosis
- Which rheumatic disease is behind the ILD?
- Complications
- Prognosis

- Treatment Goal of treatment
- Treatment

- Study Test yourself

- Connections Connections

## What it is

[Interstitial lung disease](https://durgical.com/en/conditions/interstitial-lung-disease/) that develops in a person with a systemic autoimmune rheumatic disease, such as systemic sclerosis, rheumatoid arthritis, [idiopathic inflammatory myopathy](https://durgical.com/en/conditions/inflammatory-myopathies/), [Sjögren disease](https://durgical.com/en/conditions/sjogren-disease/), lupus or [mixed connective tissue disease](https://durgical.com/en/conditions/mixed-connective-tissue-disease/). It may precede, follow or appear with the joint, [skin](https://durgical.com/en/anatomy/skin/) or muscle features.

## How to think about it

The lung is one more target of a body-wide autoimmune disease, and the antibody predicts the picture: anti-Scl-70 → fibrotic NSIP, rheumatoid factor and anti-CCP in an older male smoker → UIP, antisynthetase or anti-MDA5 → inflammatory, sometimes explosive disease. Unlike IPF, much of it is inflammation, so immunosuppression is the backbone.

See it in 3D

- [Right lower lobe](https://durgical.com/en/anatomy/inferior-lobe-of-right-lung/)
- [Left lower lobe](https://durgical.com/en/anatomy/inferior-lobe-of-left-lung/)
- [Pleura](https://durgical.com/en/anatomy/pleura/)
- [Esophagus](https://durgical.com/en/anatomy/esophagus-abdominal-part/)

## +5

- [Pulmonary arteries](https://durgical.com/en/anatomy/right-pulmonary-artery/)
- [Right ventricle](https://durgical.com/en/anatomy/right-ventricle/)
- [Diaphragm](https://durgical.com/en/anatomy/diaphragm/)
- [Skin](https://durgical.com/en/anatomy/skin/)
- [Pericardium](https://durgical.com/en/anatomy/pericardium/)

## Who gets it

A leading cause of death in systemic sclerosis and a major one in rheumatoid arthritis and myositis. It is found on CT in roughly half of people with systemic sclerosis and in up to a third of those with antisynthetase [antibodies](https://durgical.com/en/biochemistry/enzymes/immunoglobulins/) or rheumatoid arthritis; many cases are mild and found on screening. Women predominate overall, but rheumatoid arthritis–ILD is commoner in older men who smoke.

## Causes

- Systemic sclerosis, especially the diffuse form with anti- [topoisomerase I](https://durgical.com/en/biochemistry/enzymes/topoisomerases/) (anti-Scl-70) antibodies
- Rheumatoid arthritis, particularly in seropositive older male smokers
- Idiopathic inflammatory myopathies: antisynthetase syndrome (anti-Jo-1) and anti-MDA5 dermatomyositis
- Sjögren disease, [systemic lupus erythematosus](https://durgical.com/en/conditions/systemic-lupus-erythematosus/) and mixed connective tissue disease
- Interstitial pneumonia with autoimmune features: autoimmune signs that do not meet criteria for a single disease

## Risk factors

- Diffuse cutaneous systemic sclerosis and anti-Scl-70 antibodies
- High-titre rheumatoid factor or anti-CCP antibodies, older age, male sex and smoking in rheumatoid arthritis
- Antisynthetase and anti-MDA5 antibodies in myositis
- Early years after the onset of the rheumatic disease
- Gastro-oesophageal reflux and oesophageal dysmotility (systemic sclerosis)

## Pathophysiology

Systemic autoimmunity (autoantibodies, autoreactive T and B cells) → injury to the alveolar epithelium and capillary endothelium → lymphocytic inflammation and cytokines that recruit and activate fibroblasts → [a pattern](https://durgical.com/en/conditions/a-and-v-pattern-strabismus/) that depends on the disease: mainly cellular and inflammatory (NSIP, organizing pneumonia) or mainly fibrotic (fibrotic NSIP in systemic sclerosis; UIP, the most common pattern only in rheumatoid arthritis) → restriction, low [DLCO](https://durgical.com/en/physiology/diffusion-across-the-respiratory-membrane-and-dlco/) and hypoxaemia → extra injury from aspiration due to oesophageal disease (systemic sclerosis) and from the drugs used for the rheumatic disease.

## Classification

- By underlying disease: systemic sclerosis, rheumatoid arthritis, myositis, Sjögren, lupus, mixed connective tissue disease
- By pattern: nonspecific interstitial pneumonia (most common overall), usual interstitial pneumonia, organizing pneumonia, lymphocytic interstitial pneumonia, [diffuse alveolar damage](https://durgical.com/en/general-pathology/diffuse-alveolar-damage/)
- By extent and course: limited or extensive; stable or progressive pulmonary fibrosis
- Rapidly progressive ILD (classically anti-MDA5 dermatomyositis)

## Symptoms and signs

- Exertional [breathlessness](https://durgical.com/en/physiology/hypercapnia-and-dyspnea-what-excess-co-does-and-why-breathlessness-is-felt/), sometimes hidden by joint or muscle disease that limits activity
- Dry cough
- Bibasal velcro crackles
- Extrapulmonary clues: [Raynaud phenomenon](https://durgical.com/en/conditions/raynaud-phenomenon/), skin thickening, sclerodactyly, synovitis, proximal muscle weakness, 'mechanic's hands', heliotrope rash or Gottron papules, sicca symptoms
- Fever and arthritis in antisynthetase syndrome

## Red flags

- Breathlessness that worsens over weeks with skin ulcers and hand rash (anti-MDA5 rapidly progressive ILD)
- Falling [oxygen](https://durgical.com/en/pharmacology/oxygen/) saturation or a decline of FVC of 10 % or more
- Breathlessness out of proportion to lung function, or a low DLCO with preserved volumes ([pulmonary hypertension](https://durgical.com/en/general-pathology/pulmonary-hypertension/))
- Fever and new infiltrates on immunosuppression (opportunistic infection such as [Pneumocystis](https://durgical.com/en/microbiology/pneumocystis-jirovecii/))
- New cough or infiltrates after starting a drug such as [methotrexate](https://durgical.com/en/pharmacology/methotrexate/) (drug toxicity)

## Diagnosis

**Clinical**
Every new diagnosis of systemic sclerosis, myositis and other high-risk rheumatic disease is screened for ILD; every new ILD is examined for signs of connective tissue disease. A joint rheumatology–pulmonology–radiology discussion decides the diagnosis and treatment.

**Tests**
Autoantibody profile: antinuclear antibodies, anti-Scl-70, anticentromere, rheumatoid factor, anti-CCP, anti-Ro/La, anti-RNP, myositis panel (anti-Jo-1 and other antisynthetase antibodies, anti-MDA5); [creatine](https://durgical.com/en/biochemistry/molecules/creatine/) kinase. Spirometry, lung volumes and DLCO at baseline and every few months; six-minute walk with oximetry. [Bronchoscopy](https://durgical.com/en/clinical-skills/bronchoscopy/) with lavage mainly to exclude infection.

**Imaging**
High-resolution CT is the screening and diagnostic test: NSIP pattern (basal ground glass and fine reticulation with subpleural sparing), UIP pattern, or organizing pneumonia. A dilated, air-filled oesophagus suggests systemic sclerosis. Echocardiography screens for pulmonary hypertension.

## Differential diagnosis

- [Idiopathic pulmonary fibrosis](https://durgical.com/en/conditions/idiopathic-pulmonary-fibrosis/) or idiopathic NSIP
- [Drug-induced lung disease](https://durgical.com/en/conditions/drug-induced-lung-disease/) (methotrexate, [leflunomide](https://durgical.com/en/pharmacology/leflunomide/), biologics)
- Opportunistic or community infection
- Pulmonary hypertension or heart involvement
- [Aspiration pneumonitis](https://durgical.com/en/conditions/aspiration-pneumonia-and-pneumonitis/)
- [Hypersensitivity pneumonitis](https://durgical.com/en/conditions/hypersensitivity-pneumonitis/)

## Which rheumatic disease is behind the ILD?

| Disease | Clues | Antibody | Usual lung pattern |
| --- | --- | --- | --- |
| [Systemic sclerosis](https://durgical.com/en/conditions/systemic-sclerosis/) | [Raynaud](https://durgical.com/en/dermatology/cold-and-the-skin-raynaud-phenomenon-acrocyanosis-chilblains-and-cold-urticaria/), thick skin on the fingers, reflux, dilated oesophagus on CT | Anti-Scl-70 (topoisomerase I) | Fibrotic NSIP at the bases |
| [Rheumatoid arthritis](https://durgical.com/en/conditions/rheumatoid-arthritis/) | Older male smoker, symmetrical small-joint arthritis | Rheumatoid factor, anti-CCP | UIP most often, then NSIP |
| [Antisynthetase syndrome (inflammatory myopathy)](https://durgical.com/en/conditions/inflammatory-myopathies/) | Proximal weakness, mechanic's hands, arthritis, fever, Raynaud | Anti-Jo-1 and other antisynthetase antibodies | NSIP with organizing pneumonia |
| Anti-MDA5 dermatomyositis | Skin ulcers, painful palmar papules, little or no weakness | Anti-MDA5 | Rapidly progressive ILD |
| [Sjögren disease](https://durgical.com/en/conditions/sjogren-disease/) | [Dry eyes](https://durgical.com/en/conditions/dry-eye-disease/) and mouth, parotid swelling | Anti-Ro (SSA), anti-La (SSB) | NSIP; lymphocytic interstitial pneumonia with cysts |

## Goal of treatment

Find ILD early, stop or slow progression with immunosuppression and [antifibrotics](https://durgical.com/en/pharmacology/classes/antifibrotics/), treat the underlying disease and avoid infections and drug toxicity.

## Treatment

**Medical**
Immunosuppression for clinically significant or progressive disease: mycophenolate is first choice in systemic sclerosis–ILD; [azathioprine](https://durgical.com/en/pharmacology/azathioprine/), [tocilizumab](https://durgical.com/en/pharmacology/tocilizumab/), [rituximab](https://durgical.com/en/pharmacology/rituximab/) or [cyclophosphamide](https://durgical.com/en/pharmacology/cyclophosphamide/) according to the disease and severity.

**Medical**
Systemic [corticosteroids](https://durgical.com/en/pharmacology/classes/corticosteroids/) are useful in myositis and organizing pneumonia patterns but are used sparingly in systemic sclerosis, where they can trigger [scleroderma renal crisis](https://durgical.com/en/conditions/scleroderma-renal-crisis/).

**Medical**
Antifibrotic therapy ([nintedanib](https://durgical.com/en/pharmacology/nintedanib/), and [pirfenidone](https://durgical.com/en/pharmacology/pirfenidone/) in some cases) when fibrosis keeps progressing despite treatment; anti-MDA5 rapidly progressive ILD needs early combined intensive therapy.

**Rehabilitation**
Pulmonary rehabilitation, oxygen for hypoxaemia, smoking cessation, vaccination, prophylaxis against Pneumocystis with intense immunosuppression, and treatment of reflux.

**Surgical**
[Lung transplantation](https://durgical.com/en/conditions/the-lung-transplant-recipient/) in selected patients with end-stage disease and controlled extrapulmonary disease.

**Follow-up**
Regular lung function, oximetry and CT when needed; echocardiography for pulmonary hypertension; monitoring blood counts and [liver](https://durgical.com/en/anatomy/liver/) tests on immunosuppressants.

## Complications

- Progressive pulmonary fibrosis and chronic respiratory failure
- Pulmonary hypertension
- Opportunistic infections from immunosuppression
- Acute exacerbation of ILD
- [Lung cancer](https://durgical.com/en/conditions/lung-cancer/)
- Drug toxicity

## Common traps

- **No joint or skin disease means it cannot be CTD-ILD**: the lung can come first, especially in antisynthetase syndrome; test autoantibodies in every new ILD
- **High-dose corticosteroids are the safe first step in every CTD-ILD**: in systemic sclerosis they can trigger scleroderma renal crisis; mycophenolate is the usual first choice there
- **Anticentromere is the lung antibody of scleroderma**: anti-Scl-70 predicts ILD, while anticentromere (limited disease) points to pulmonary hypertension
- **New infiltrates on methotrexate mean the ILD is progressing**: first exclude infection (including Pneumocystis) and drug toxicity
- **Little muscle weakness means mild lung disease**: anti-MDA5 dermatomyositis has little or no weakness but can cause rapidly progressive, often fatal ILD

## Prognosis

Generally better than idiopathic pulmonary fibrosis, except for UIP-pattern rheumatoid arthritis–ILD and anti-MDA5 rapidly progressive ILD, which can be fatal within months. Extensive disease on CT, a low or falling FVC and DLCO, and pulmonary hypertension predict worse survival.

## Test yourself

Think of the answer, then tap the question to see it.

## Which antibody in systemic sclerosis carries the highest risk of interstitial lung disease?

Anti-topoisomerase I (anti-Scl-70), usually with diffuse cutaneous disease; anticentromere is linked to pulmonary hypertension instead.

## Which connective tissue disease most often shows a UIP pattern on CT?

Rheumatoid arthritis; most other connective tissue diseases show nonspecific interstitial pneumonia.

## Why are high-dose corticosteroids avoided in systemic sclerosis–ILD?

They can trigger scleroderma renal crisis ([acute kidney injury](https://durgical.com/en/conditions/acute-kidney-injury/) with malignant hypertension).

## Which myositis antibody is linked to rapidly progressive, often fatal ILD?

Anti-MDA5, often with skin ulcers, little or no muscle weakness (amyopathic dermatomyositis).

## A 45-year-old woman has 3 months of dyspnoea, fever, proximal weakness and cracked skin on the sides of her fingers; CK is high and CT shows basal ground glass. Which antibody, and what treatment?

Anti-Jo-1 (antisynthetase syndrome): myositis, mechanic's hands and NSIP or organizing pneumonia. After excluding infection, immunosuppression (corticosteroids plus a steroid-sparing agent).

[Add to my cards (5)](https://durgical.app/estudiar/?add=/en/conditions/connective-tissue-disease-associated-interstitial-lung-disease/)

## Why it happens

- [Dermatomyositis and antisynthetase syndrome](https://durgical.com/en/general-pathology/dermatomyositis-and-antisynthetase-syndrome/)

## Connections

## In physiology 1

- [Diffusion across the respiratory membrane and DLCO](https://durgical.com/en/physiology/diffusion-across-the-respiratory-membrane-and-dlco/)

## Related conditions 13

- [Interstitial lung disease](https://durgical.com/en/conditions/interstitial-lung-disease/)
- [Idiopathic pulmonary fibrosis](https://durgical.com/en/conditions/idiopathic-pulmonary-fibrosis/)
- [Systemic sclerosis (scleroderma, including CREST)](https://durgical.com/en/conditions/systemic-sclerosis/)
- [Rheumatoid arthritis](https://durgical.com/en/conditions/rheumatoid-arthritis/)
- [Inflammatory myopathies (dermatomyositis, polymyositis)](https://durgical.com/en/conditions/inflammatory-myopathies/)
- [Sjögren disease](https://durgical.com/en/conditions/sjogren-disease/)
- [Mixed connective tissue disease](https://durgical.com/en/conditions/mixed-connective-tissue-disease/)
- [Systemic lupus erythematosus](https://durgical.com/en/conditions/systemic-lupus-erythematosus/)
- [Raynaud phenomenon](https://durgical.com/en/conditions/raynaud-phenomenon/)
- [Pulmonary hypertension and cor pulmonale](https://durgical.com/en/conditions/pulmonary-hypertension-and-cor-pulmonale/)
- [Drug-induced lung disease](https://durgical.com/en/conditions/drug-induced-lung-disease/)
- [Cryptogenic organizing pneumonia](https://durgical.com/en/conditions/cryptogenic-organizing-pneumonia/)

## See all 13

- [Pneumocystis pneumonia (PCP)](https://durgical.com/en/conditions/pneumocystis-pneumonia/)

Educational information, not medical advice. For any symptom, see a health professional.

Sources: [Connective Tissue Disease–Associated Interstitial Lung Disease](https://www.ncbi.nlm.nih.gov/books/NBK559094/) (StatPearls (NCBI Bookshelf), 2026); [Systemic Sclerosis (Scleroderma)](https://www.ncbi.nlm.nih.gov/books/NBK430875/) (StatPearls (NCBI Bookshelf), 2024).

[← All conditions](https://durgical.com/en/conditions/)

## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake

Representative model, for educational purposes only.

---
Source: https://durgical.com/en/conditions/connective-tissue-disease-associated-interstitial-lung-disease/
License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/conditions/connective-tissue-disease-associated-interstitial-lung-disease/
